Descartes-08 in Autoantibody Myositis

This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).

NCT Number	NCT07391605
Lead Sponsor	Cartesian Therapeutics
Conditions	Antisynthetase Syndrome
Enrollment	60 participants
Start Date	2026-04-28
Primary Completion	2027-11 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-14